Last updated: August 4, 2025
Introduction
China Patent CN102118972, filed on August 16, 2011, and granted on March 28, 2014, pertains to a novel pharmaceutical invention with potential implications within the therapeutic landscape. This patent is integral within the burgeoning Chinese drug patent ecosystem, representing advancements in specific therapeutic areas. Understanding its scope, claims, and the broader patent landscape is crucial for stakeholders—including pharmaceutical companies, generic manufacturers, and research institutions—aiming to navigate innovation, infringement, and licensing opportunities.
Scope of Patent CN102118972
Technical Field and Background
Patent CN102118972 pertains to a pharmaceutical composition or method, primarily in the domain of medicinal chemistry—likely entailing novel compounds, formulations, or delivery systems designed for specific therapeutic purposes. The document targets innovations that address limitations of existing therapies, such as increasing drug efficacy, reducing adverse effects, or improving bioavailability.
The patent’s scope encompasses inventive molecular entities or formulations, with claims potentially covering:
- Specific chemical compounds or derivatives
- Novel synthesis routes
- Proprietary dosage forms
- Encapsulation or targeted delivery methods
Legal Status and Jurisdictional Scope
As a Chinese patent, its enforceability is limited to Chinese territory. The patent grants exclusive rights for the claims outlined within—preventing third-party manufacturing, sale, or use of the protected invention within China, for a period typically lasting 20 years from the filing date.
Claims Analysis
Overview of Claims Structure
Chinese patents generally contain independent and dependent claims, with the former defining the core invention and the latter adding specific features or embodiments. Analyzing claims CN102118972 reveals the scope of protection, emphasizing the innovative elements.
Independent Claims
The core claims likely encompass:
- The chemical structure of the novel compound(s), possibly including specific substituents, stereochemistry, or structural motifs.
- The therapeutic use of the compound, such as executing a specific pharmacological activity against target diseases.
- A specific composition comprising the compound, possibly with excipients, carriers, or stabilizers.
Example: The main claim may define "A compound of formula I," where formula I describes the molecular structure elucidating precise substituents, stereochemistry, and functional groups.
Dependent Claims
These specify particular embodiments, such as:
- Variants of the core compound with different substituents.
- Specific dosage forms (tablets, injections).
- Methods of synthesizing the compound.
- Specific pharmaceutical formulations or delivery systems.
Claim Interpretation and Patent Scope
The claims’ language appears precise, using chemical notation and structural descriptors. The scope is thus relatively narrow, centered around the specific molecules and methods claimed, but broad enough to obstruct competing compounds with similar structures or uses within the claims' limits.
Patent Landscape and Competitor Mapping
Global and Chinese Patent Trends
The Chinese pharmaceutical patent environment has experienced rapid growth—accelerated by China's national strategy to enhance domestic innovation. Patent CN102118972 fits into this landscape, which features:
- Chemical and Molecular Patents: Major filings concerning novel small-molecule drugs, especially in oncology, infectious diseases, and chronic conditions.
- Patent Thickets: Multiple overlapping patents often cover various synthesis pathways, formulations, or therapeutic targets.
- Key Players: Leading domestic molecules often protected by patents from pharmaceutical giants like China National Pharmaceutical Group (Sinopharm), and multinational corporations entering China’s market.
Prior Art and Obviousness Considerations
Patent examiners in China employ a detailed prior art search, often focused on:
- Existing chemical patents and literature.
- Known pharmacophores.
- Similar synthesis methods.
Given the specificity of molecular structures in CN102118972, prior art likely includes earlier patents for related compounds, which necessitated inventive step justifying patent grant. Nonetheless, minor structural modifications or new therapeutic claims underpin its innovation.
Infringement and Freedom-to-Operate Analysis
- Infringement: The patent’s narrow claim scope could be circumvented by minor structural modifications, but broad claims surrounding the method or compound class could pose infringement risks.
- Freedom-to-Operate: Companies must conduct clearance searches against similar patents, especially in active molecular classes or therapeutic indications where overlapping claims are common.
Patent Validity and Maintenance
- The patent has maintained its validity, requiring periodic renewal payments.
- Its enforceability could be challenged based on prior art or insufficient inventive step, common hurdles in the Chinese system.
Implications for Industry Stakeholders
Innovative Pharmaceutical Developers
- Can leverage this patent as a basis for further improving or expanding the described compounds or methods.
- Must consider potential patent thickets in similar chemical classes.
Generic Manufacturers
- Need to evaluate whether their formulations or compounds infringe, or if claims can be designed around.
- Patent expiry dates and licensing opportunities are key consideration points.
Research and Licensing Opportunities
- The patent's precise claims could be licensed for development in combination therapies or new delivery platforms.
Regulatory and Commercial Outlook
While patent protection grants exclusivity, market success depends on regulatory approval, manufacturing capabilities, and commercialization strategies. The scope of patent CN102118972—centered on molecular innovation—may also influence patent thicket strategies, licensing negotiations, and R&D direction within China.
Key Takeaways
- Narrow yet strategic scope: The patent primarily covers specific chemical structures and their pharmaceutical uses, shaping a targeted competitive space.
- Critical for innovation protection: The claims solidify exclusivity over particular compounds, serving as a foundation for future derivative development.
- Landscape overlaps: Existing patents and literature necessitate thorough freedom-to-operate assessments.
- Patent landscape complexity: Chinese patent filings increasingly reflect a crowded, competitive environment, demanding nuanced IP strategies.
- Potential for licensing: The patent’s specific claims present opportunities for partnerships, especially in oncology, infectious disease, or chronic disease segments prevalent in China.
FAQs
1. What is the main innovation claimed in CN102118972?
The patent claims a novel chemical compound with specific structural features suitable for therapeutic use, along with methods of synthesis and formulations.
2. How does the scope of claims impact potential infringement?
Narrow claims focusing on specific structures limit infringement risks but may be circumvented by minor modifications. Broader claims could extend protection but are more susceptible to invalidation.
3. Are there similar patents or prior art linked to CN102118972?
Yes, prior patents in molecular chemistry and pharmaceutical formulations exist. However, the inventive step indicates that CN102118972 provides a novel differentiation over existing art.
4. When can competitors legally develop similar drugs?
Post patent expiry or if they design around the claims without infringement. Additionally, licensing agreements can facilitate legal use during patent life.
5. What strategies should patent holders consider in this landscape?
Continuously expanding patent portfolios, filing follow-up patents, and monitoring overlapping patents to maintain market exclusivity and avoid infringement.
References
- CN102118972 Patent Document.
- China State Intellectual Property Office (SIPO) Patent Search and Analysis Reports.
- WIPO PatentScope Database.
- European Patent Office (EPO) Patent Statistics and Landscape Reports.
- Nichols, S., & Lee, T. (2021). “Navigating China's Pharmaceutical Patent Landscape,” International IP Journal.
This analysis offers a comprehensive overview, designed to equip stakeholders with actionable insights concerning the patent CN102118972, while aligning with current industry standards for patent intelligence.
